INTRODUCTION
============

The ability to balance between scanning the environment for signals of potential danger and dismissing negative cues when irrelevant to the current goals is an adaptive function. Anxiety and depression are characterized by aberrant attention to emotional stimuli, involving alterations in ocular exploration of the stimuli. For example, highly anxious individuals can show initial hypervigilance to images appraised as potentially threatening ([@bib1]; [@bib37]). This can be followed by avoidance, leading to misattributions in the actual meaning of stimuli and possibly having a crucial role in maintaining symptoms ([@bib1]; [@bib9]). In addition, depression has been associated with a prolonged maintenance of attention over negative pictures ([@bib4]; [@bib6]; [@bib22]) and reduced attention allocation to positive stimuli ([@bib12]), consistent with clinical symptoms of overdwelling on negative stimuli ([@bib32]) and anhedonia.

Avoidance of the processing of social cues such as faces may have knock-on effects on social interactions. The eye region tends to attract attention when people look at faces and is crucial for gender and identity discrimination and for emotion recognition ([@bib35]; [@bib47]). Biases in eye-region exploration have been mostly investigated in disorders with most evident interpersonal difficulties, such as autism and social phobia ([@bib26]). For example, socially anxious individuals showed a hypervigilant-avoidant response to threatening facial expressions, which becomes purely avoidant when put in a socially challenging situation ([@bib19]). Anxiety, interpersonal sensitivity, and dysphoria often co-occur in clinical samples and also in the personality trait of neuroticism, characterized by a predisposition to negative affect and increased vulnerability to emotional disorders ([@bib10]; [@bib28]); however, it is poorly understood how this relates to attentional processes towards social stimuli.

Pharmacological treatment of anxiety and depression remains relatively non-specific with selective serotonin reuptake inhibitors (SSRIs) being commonly used in both diagnostic categories ([@bib30]). Antidepressant medication has been shown to modulate the processing of facial stimuli early in treatment in healthy volunteers and depressed patients, promoting a positive pattern of social information processing that is believed to contribute in time to symptom resolution ([@bib40]). On direct tasks of emotional attention, SSRIs have been shown to decrease vigilance to fearful facial expressions in healthy volunteers ([@bib34]). However, it is unknown whether SSRIs are also able to modify attention deployment via ocular exploration of facial stimuli early in treatment in samples with negative attentional biases.

This question can be addressed by selecting a population at risk for psychopathology with emotion-processing biases typical of anxiety and depression, such as subjects with high neuroticism traits ([@bib5]; [@bib36]). For example, highly neurotic volunteers showed reduced recognition of positive facial expressions of happiness ([@bib7]), and a recent study reported a positive correlation between neuroticism and gaze duration over the eye region of fearful faces ([@bib38]). Previous studies have also revealed that short-term antidepressant administration is not only able to reverse the negative biases in self-referential processing characterizing vulnerability to depression ([@bib13]) but can also increase threat-related processing in visual attentional brain areas in the same group ([@bib14]). However, the relationship between changes in attention towards facial stimuli and changes in negative attentional bias following SSRI treatment in this group has not been investigated despite the potential for important interactions.

The aim of our research was (a) in Study 1, to investigate the presence of attentional biases in ocular exploration of emotional facial expressions (measured by eye-movement tracking) in a population with high and low levels of neuroticism (associated with approximately a threefold difference in risk for depression and anxiety ([@bib28])); and (b) in Study 2, to test whether short-term repeated SSRI administration can modulate attentional biases in ocular exploration of emotional facial expressions in the same population at risk for psychopathology, compared with placebo. Given the anxious-depressive phenotype of high neuroticism, we hypothesized that (a) in Study 1, individuals with high neuroticism would present attentional biases in ocular exploration of facial expressions. As previous behavioral data ([@bib3]) and neuroimaging research ([@bib21]; [@bib24]) suggest that short-term repeated SSRI administration can modify initial attention allocation and covert vigilance for negative facial expressions, we also hypothesized that (b) in Study 2, 7 days of SSRI treatment would be able to normalize the biases in ocular exploration of faces associated with neuroticism and (c) this would be correlated with the ability to recognize emotional facial expressions in a separate task.

MATERIALS AND METHODS
=====================

STUDY 1 Ocular Exploration of Emotional Facial Expression: High *vs* Low Neuroticism
------------------------------------------------------------------------------------

### Volunteers and design

The ethics committee Oxfordshire REC B (Ref. 09/H0605/60) approved the study. All participants gave written consent. Fifty subjects (18 males; mean age =28.93±7.7 years) were recruited from the general population, based on neuroticism scores on the Eysenck Personality Questionnaire (EPQ) ([@bib15]) either low (⩽6) or high (⩾16), approximately corresponding to the mean neuroticism scores of the same aged general population ([@bib16]) +1 SD, which conveys an 50--60% increase in lifetime risk for developing depression ([@bib28]). Participants were screened for axis I disorders using the Structured Clinical Interview for DSM-IV ([@bib17]) and completed the State-Trait Anxiety Inventory ([@bib42]), Beck Depression Inventory ([@bib2]), Dysfunctional Attitude Scale ([@bib46]), and visual analogue scales (VAS) rating happiness, sadness, hostility, alertness, anxiety, and calmness. Three subjects were excluded owing to history of depression (before data collection, all from the high neuroticism group) and three owing to bad quality of data recording (two from the high and one from the low neuroticism group). The final sample comprised 44 subjects (17 males, mean age=29.6±7.9 years), of which 24 had low neuroticism scores (Low Ns) (10 males, mean *N*=2.62±1.4) and 20 had high neuroticism scores (High Ns) (7 males, mean *N*=18.45±2.2). Gender imbalance in the High Ns group reflects the personality trait distribution in the general population ([@bib33]).

### Gender discrimination task

A task previously adopted in fMRI experiments with a similar sample was used ([@bib8]; [@bib14]). Participants were presented with 8 faces on a computer displaying prototypical expressions of fear and happiness, and a neutral face (29) morphed at 30% (low), 60% (medium), and 100% (high intensity) of the expression along the neutral-prototypic continuum. A total 168 stimuli were presented in a random order for 500 ms each, with intertrial interval varying according to a Poisson distribution (mean=5000 ms). Participants indicated the gender of each face by a key press. Behavioral responses (accuracy and RT) were recorded using Presentation (Neurobehavioral Systems, Albany, CA).

### Eye-movement recording

During the task, eye movements were recorded using an infrared eye-tracking system (ISCAN, Woburn, MA) at a rate of 60 Hz. A chin rest ensured a stable position of the head at 100-cm screen distance. Eye position was calibrated using a five-point calibration procedure.

Data were analyzed using the i-LAB software ([@bib20]) under the Matlab environment (Mathworks, Inc.).

For each trial, blinks were filtered using the pupil-size parameter, and missing points were replaced using a linear interpolation between preblink and postblink values. To derive eye-movement measures, three rectangular regions of interest (ROIs) were drawn covering: (1) the eye region, (2) the mouth and lower nose region, and (3) the whole face. Parameters were computed as the proportion of ocular movements made over eyes/mouth ROI within the total ocular movements made over the whole face.

Four dependent measures were extracted for analysis: number of fixations, scanpath length, scanning time, and gaze maintenance. Fixations represent the frequency of stationary gaze points during scanning and were defined as a set of eye positions within a defined area (0.30 × 0.30 degree area) for a selected amount of time (100 ms) and calculated using a velocity/distance algorithm ([@bib20]). Scanpath length refers to the summed distances traveled by the eye during scanning, measured in degrees of visual angle (expressed in pixels). Scanning time refers to the time spent by the eye traveling over the stimuli, calculated in ms. The gaze maintenance calculation indicated whether gaze was or not maintained in the selected ROI for the entire trial duration (500 ms).

For each outcome measure, a cutoff of minimum 25% valid trials was adopted in order for data from any individual to be included.

### Statistical analysis

Box plots were used to identify outliers. Values \>3 box-lengths from the 75th percentile (box-length=interquartile range) were excluded.

Behavioral data (gender discrimination mean accuracy and mean RT) were analyzed using repeated-measures ANOVAs, with group (High *vs* Low Ns) as the between-subject variable and emotion (fearful, happy) and intensity of facial expression (high, medium, low) as the within-subjects variables. The eye-movement parameters were analyzed using repeated-measures ANOVAs, first over the whole face ROI with group (High *vs* Low Ns) as the between-subject variable and emotion (fearful, happy) and intensity of facial expression (high, medium, low) as the within-subjects variables. Ocular exploration over different face areas was analyzed, including the additional within-subjects variable of within-face ROIs (eyes, mouth) to the repeated-measures ANOVAs. The interpretation of significant interaction effects was aided by the use of *post hoc* analysis (Bonferroni) to compare between levels of the different factors and by use of simple main-effect analyses. Independent samples *t*-tests were performed to examine group differences in affect and personality ratings. Correlation analyses were run to check for relationships between eye-movement parameters and behavioral responses and affect ratings in the High Ns group. In order to simplify correlation analysis, eye-movement data were collapsed across different facial expression intensities.

STUDY 2 Ocular Exploration of Emotional Facial Expression: 7 Days Citalopram *vs* Placebo
-----------------------------------------------------------------------------------------

### Volunteers and design

Recruitment and screening measures were the same as in Study 1, but only individuals with High Ns were selected (⩾16 on neuroticism scale of the EPQ) ([@bib15]). Forty-seven participants were recruited from the general population; five were excluded owing to history of depression (before data collection and randomized group allocation), and six owing to bad quality of data recording (after data collection; four from the citalopram, two from the placebo group). Three more participants (2 from the citalopram, 1 from the placebo group) were excluded as outliers (see definition above), leaving a total sample of 33 (20 males, mean age=23.6±6.1 years), of which 16 received citalopram (10 males, mean *N*=18.44±2.4) and 17 placebo (10 males, mean *N*=19.76±1.8). Participants were randomly allocated to receive identical capsules of citalopram 20 mg or placebo, instructed to take them every day after breakfast, and tested on the seventh day of administration, avoiding caffeinated drinks from 2 h before testing.

### Gender discrimination task and eye-movement recording

The experimental methods were the same as in Study 1.

### Facial expression recognition task (FERT)

In this study, participants performed an additional task (FERT) previously shown to be sensitive to antidepressant manipulation ([@bib23]), where subjects are asked to label emotional facial expressions presented on a screen for 500 ms at intensities varying between 10 and 100%. Correct responses and misclassifications are recorded, and accuracy is measured calculating the average expression intensity threshold needed to correctly identify each emotion ([@bib7]). Eye movements were not recorded during the FERT.

### Statistical analysis

The analysis methods were the same as in Study 1. In the repeated-measures ANOVAs, treatment group (drug *vs* placebo) was entered as the between-subjects variable. A correlation analysis was also run between eye-movement parameters and facial expression intensity threshold values for correct emotion recognition on the FERT, to explore whether emotion recognition accuracy was related to patterns of ocular face exploration.

RESULTS
=======

For both studies, results from personality and affect ratings, and behavioral performance on the gender discrimination task, are reported in the [Supplementary Material](#sup1){ref-type="supplementary-material"} ([Supplementary Tables S1--S4](#sup1){ref-type="supplementary-material"}). Eye-movement data are only reported for the ocular measures with sufficient valid trials and for which significant between-group differences were found. All *p*-values reported are Bonferroni corrected for multiple comparisons.

STUDY 1 Ocular Exploration of Emotional Facial Expression: High *vs* Low Neuroticism
------------------------------------------------------------------------------------

### Gender discrimination task: eye movements

*Whole face area*. Recording of eye movements did not show any significant between-group differences in ocular exploration of different emotional expressions (all *p*\'s\>0.1).

*Eyes vs mouth---gaze maintenance*. In the emotion × intensity × ROI × group ANOVA analyzing gaze maintenance over different areas of the facial expressions, a significant ROI (eyes *vs* mouth) × group (High *vs* Low Ns) interaction was present (F(1,42)=10.328, *p*=0.003; [Table 1](#tbl1){ref-type="table"}). This showed that High Ns spent less time gazing at the eyes region and more at the mouth region of faces compared with Low Ns (eyes ROI: F(1,42)=4.949, *p*=0.032; mouth ROI: F(1,42)=10.190, *p*=0.003; [Figure 1](#fig1){ref-type="fig"}).

*Correlations with behavioral performance and affect ratings*. Correlation analysis between gaze parameters and affect ratings before testing revealed a significant negative correlation between self-ratings of hostility on VAS and gaze maintenance over the eye region of both happy (*R*=−0.598, *p*=0.007) and fearful faces (*R*=−0.640, *p*=0.002) in the High Ns group.

STUDY 2 Ocular Exploration of Emotional Facial Expression: 7 Days Citalopram *vs* Placebo
-----------------------------------------------------------------------------------------

### FERT

To compare accuracy at labeling positive *vs* negative emotions, thresholds for correct recognition were aggregated for negative (sad, angry, and fearful) and positive (happy, surprised) facial emotional expressions. There was a significant valence × treatment group interaction (F(1,36)=5.60, *p*=0.023), with subjects on citalopram requiring a lower intensity of emotional expression to correctly recognize positive *vs* negative emotions compared with subjects on placebo. Detailed task results are reported in [Supplementary Materials](#sup1){ref-type="supplementary-material"} ([Supplementary Table S5](#sup1){ref-type="supplementary-material"}).

### Gender discrimination task: eye movements

Mean results for each group are described in [Table 2](#tbl2){ref-type="table"}.

*Whole face area---gaze maintenance*. In the emotion × intensity × group ANOVA analyzing gaze maintenance, a significant between-group difference was found irrespective of facial expression and intensity, driven by subjects on citalopram maintaining their gaze over the faces for the whole trial duration more than subjects on placebo (main effect of group: F(1,31)=11.664, *p*=0.002; [Figure 2](#fig2){ref-type="fig"}).

*Whole face area---scanpath length*. In the emotion × intensity × group ANOVA analyzing the scanpath length, all subjects showed larger degree of exploration of faces with medium emotional intensity (F(2,62)=6.024, *p*=0.004). A significant two-way interaction was found between group and intensity of facial expression (F(2,62)=3.651, *p*=0.032), such that within the placebo but not within the citalopram-treated group participants showed larger degree of spatial exploration of medium compared with low and high intensity faces (placebo: F(2,62)=6.372, *p*=0.005; drug: F(2,62)=2.038, *p*=0.149). A significant three-way interaction was also present between group, emotion, and intensity of facial expression (F(2,62)=3.692, *p*=0.031, (Cohen\'s *d*=0.64)), indicating that individuals on citalopram tended to spatially explore the fearful faces of medium intensity less compared with individuals on placebo (F(1,31)=3.255, *p*=0.083) ([Figure 3](#fig3){ref-type="fig"}).

*Whole face area---scanning time*. In the emotion × intensity × group ANOVA analyzing the amount of time spent scanning faces, a significant between-group difference was found irrespective of facial expression and intensity, driven by subjects on citalopram scanning all faces longer compared with subjects on placebo (F(1,31)=9.867, *p*=0.004) ([Supplementary Figure S1](#sup1){ref-type="supplementary-material"}).

*Eyes vs mouth---gaze maintenance*. In the emotion × intensity × ROI × group ANOVA analyzing the proportion of gaze maintenance over different areas of the facial expressions, a significant main effect of group was found driven by subjects on citalopram maintaining their gaze for the whole trial duration over both eyes and mouth areas of all faces more than subjects on placebo (F(1,31)=6.378 *p*=0.017).

*Correlations with behavioral performance and affect ratings*. A significant positive correlation was observed between gender discrimination accuracy for fearful faces and scanning time (*R*=0.374, *p*=0.027). Instead, a negative correlation was found between gender discrimination accuracy for fearful faces and scanpath length (*R*=−0.366, *p*=0.031). No correlations were found with affect ratings.

*Correlations with emotion recognition*. A significant negative correlation was found between the intensity threshold needed to correctly recognize happy faces and gaze maintenance over the whole area of happy facial expression (*R*=−0.358, *p*=0.044) and between the number of misclassifications of happy faces and both gaze maintenance and scanning time over the whole area of happy facial expression (*R*=−0.518, *p*=0.002; *R*=−0.473, *p*=0.006). Given the significant between-group difference in facial expression recognition, driven by the citalopram-treated group performing better on positive faces, an exploratory regression analysis was also run to test whether emotion recognition was predicted by the pattern of ocular exploration of the faces. A significant predictive model was found with recognition threshold of positive faces as the dependent variable and group, ocular scanning time over happy faces, and the interaction between group and scanning time as independent variables (*R*=0.503, dF=(3,31), F=3.157, *p*=0.040). Scanning time over happy faces and the interaction between group and scanning time over happy faces were significant predictors of positive emotion recognition performance (*β*=−1.366, *p*=0.018 and *β*=1.181, *p*=0.021; [Supplementary Figure S2](#sup1){ref-type="supplementary-material"}).

DISCUSSION
==========

This study investigated whether neuroticism affects ocular exploration of emotional faces and whether this can be modulated by antidepressant drug treatment. Using a gender-discrimination task of fearful and happy faces with different emotional intensity, we found that: (a) subjects with high neuroticism present a different pattern of ocular exploration of faces compared with subjects with low neuroticism, characterized by reduced gaze maintenance over the eyes region of the face, irrespective of emotional expression; (b) short-term repeated SSRI administration increased eye-gaze maintenance and scanning time over all facial expressions, irrespective of emotion type and intensity, compared with placebo in a high-risk sample with high neuroticism. The same treatment also reduced the spatial extension explored by eye movements over faces of medium emotional intensity, and this was significant for fearful faces. Moreover, (c) eye-movement pattern predicted performance on facial expression recognition on a separate task. These results occurred in the absence of any subjective modifications in mood or anxiety ([Supplementary Material](#sup1){ref-type="supplementary-material"}), consistent with the model by which antidepressants\' action on the processing of emotional information precedes changes in affective state ([@bib40]).

Effects of High Neuroticism on Ocular Exploration of Face Stimuli
-----------------------------------------------------------------

Our study indicates that high neuroticism is characterized by an attentional bias away from salient face regions, which is not affected by emotional valence of the facial expression and is indexed by an abnormal pattern of ocular face exploration. High Ns avoided holding their gaze over the eye region for the whole trial duration, and general face avoidance was significantly correlated with self-rated hostility. This suggests that High Ns may avoid engaging with socially salient stimuli such as faces, reflecting a self-perceived negative disposition towards interpersonal contact. Previous studies have reported a similar pattern in socially phobic patients ([@bib25]). Although we did not collect measures of social anxiety, stress during social interactions is a well-recognized feature of the high neurotic phenotype, contributing to the higher risk for social anxiety ([@bib11]; [@bib45]). Interestingly, this avoidant ocular exploration pattern is consistent with reduced neural response to faces (irrespective of emotional expression) in the amygdala in the same population ([@bib14]).

Differences in the task demands could explain the discrepancy between our findings and that by [@bib38], who reported that increased scanning over the eye region, in particular of fearful faces, is associated with high neuroticism during an overt emotion discrimination task. It is possible that when explicitly cued to respond to the emotional expression of the face, highly neurotic subjects can orient their attention to the eyes, which they otherwise avoid when less relevant to their contingent objective. If this were true, the increased eye region exploration over fearful eyes found by [@bib38] could represent a task-driven strategy, consistent with a recent meta-analysis showing that heterogeneity of results from attention orienting and maintenance data is often context dependent ([@bib1]). Another explanation could lie in our sample focused on High N individuals, whereas [@bib38] using a continuous measure: 'extreme\' neuroticism, is more likely to present prominent socially anxious features, which could explain an avoidant pattern of eye region exploration ([@bib18]).

Together, these data suggest that high neuroticism is associated with inadequate capacity to maintain attention over key areas of face stimuli, which could in turn underpin interpersonal difficulties often presented by this group. This may contribute to increased risk of developing anxiety consistent with clinical models ([@bib9]) and to lower quality of life, influenced by hypersensitivity to interpersonal stressors and lack of social support ([@bib27]; [@bib31]). Of note, neuroticism is a heterogeneous and multifaceted construct. Our task of covert attention towards emotional facial expression with a short stimulus presentation allows a global assessment of emotion-processing biases, more in particular to those related to general anxiety (hypervigilance---avoidance of negative stimuli) and social anxiety (avoidance of the eye region of faces). Future studies could employ larger samples and identify population subgroups with high neuroticism characterized by more prominent dysphoric, generally anxious, and socially anxious traits. This could be combined with tasks showing concurrent negative and positive facial expressions and longer stimulus presentation in order to investigate more extensively the presence of attentional biases associated with anxiety and depression, respectively.

Effect of SSRIs on Ocular Exploration of Face Stimuli
-----------------------------------------------------

We also found that SSRIs can modulate attentional biases towards faces in a high-risk sample early in treatment, by directly increasing gaze maintenance over the internal features of faces. This suggests that an initial SSRIs\' effect in anxious individuals could be to partly correct their dysfunctional pattern of ocular exploration of faces.

Initial attention allocation to salient stimuli is associated with amygdala activation ([@bib44]). The present finding is therefore consistent with neuroimaging data showing that short-term repeated SSRI administration to High Ns increased the amygdala signal to facial expression irrespective of emotion type ([@bib14]). The causal mechanism operating between amygdala activation and eye gaze movements remains unclear. The first neural response could precede attention deployment, guiding the eyes to explore the detected stimuli ([@bib29]), but time spent gazing over the stimuli could equally increase the limbic neural signal ([@bib39]). SSRI-driven modifications could occur at one or both stages of this process.

Notably, in the citalopram-treated group prolonged attention to faces (as measured by the ability to hold the gaze on the face for the entire trial and by the time spent scanning faces) was predictive of better performance in the gender discrimination task and to a more accurate discrimination of positive expressions in a separate facial expressions recognition task. High Ns find happiness recognition particularly difficult compared with non-vulnerable samples ([@bib7]), and the current data suggest that recognition of positive emotional facial expressions improves early with SSRI treatment in this group. Although our data cannot make any causal inference, they suggest that modulation of basic eye-movement and face-exploration parameters by SSRIs are associated with correction of this negative bias in emotion recognition. Further investigations should confirm whether the capacity of different antidepressant agents to shift biases in facial expression recognition in unselected populations ([@bib40]) is similarly associated with effects on ocular exploration.

By contrast, short-term repeated SSRI administration did not modify the preference for exploring the mouth rather than the eye region seen in High Ns in Study 1. This suggests that antidepressants may produce a non-specific effect on gaze maintenance over faces. In a previous research, 2 weeks of citalopram administration in healthy volunteers increased eye contact compared with placebo in an interaction task with a stranger ([@bib43]). Future studies with samples also characterized on social anxiety dimensions, more naturalistic experimental settings, and longer treatment duration could clarify whether the SSRI-mediated increase in face exploration after 1 week would also facilitate with time the reversal of the eye region avoidance when this is present.

Interestingly, citalopram-treated individuals also tended to spacially explore the face area less compared with placebo-treated ones, but this effect appeared prominent for fearful faces of medium intensity. Anxious individuals have been shown to spatially explore larger areas of faces while holding the eye gaze for shorter time duration over the face ([@bib25]). This could reflect a 'scanning style\' of faces that avoids to properly stop over those cues holding potential danger and can impair accurate processing ([@bib1]). This result should be treated with caution given the relatively small sample, with a medium effect size of the comparison. Accordingly, in our sample the spatial extension of eye movements was negatively correlated with gender discrimination accuracy. Hence, the combination of SSRI-induced changes in ocular exploration over fearful expressions and over all faces could lead to a more functional attention deployment toward socially salient stimuli, contributing to the long-term anxiolytic effect of antidepressants. If this were true, antidepressant action would appear to occur via an 'exposure\' mechanism similar to cognitive-behavioral treatments, as we have previously suggested ([@bib14]).

Summary
-------

In summary, our results demonstrate that short-term antidepressant administration can modify the pattern of attention for facial stimuli by changing ocular movements exploring faces in subjects at risk for depression and anxiety, before any changes in affect. Our data illustrate how antidepressant medication could reduce the difficulties in extracting information from facial stimuli by increasing evaluative capacity. This can have different clinical impact depending on preexisting attentional biases. It might temporarily increase anxiety in subjects hypervigilant for threat, but it can also increase positive affect in subjects generally avoidant of social contacts and thus deprived of positive interpersonal feedback. This is consistent with the variable responses to SSRI treatment in clinical practice, including the so-called early 'anxiogenic effects\' ([@bib41]; [@bib48]). Further studies will need to verify whether our findings can be extended to clinical populations and to investigate how modification of ocular exploration of socially salient stimuli influences remission of anxious and depressive symptoms over time.
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![Subjects with High Neuroticism scores maintain less frequently the gaze over the eye region and more over the mouth region for the whole duration of a trial compared with subjects with Low Neuroticism scores.](npp2014159f1){#fig1}

![Citalopram-treated subjects with High Neuroticism maintain the gaze more over all faces for the whole trial duration during a gender discrimination task, compared with those on placebo.](npp2014159f2){#fig2}

![Citalopram-treated subjects with High Neuroticism explore smaller extensions of fearful faces with medium emotional intensity compared with those on placebo.](npp2014159f3){#fig3}

###### Eye Movements Over Facial Expressions During a Gender Discrimination Task in Subjects with Low (Low Ns, *N*=24) and High Neuroticism (High Ns, *N*=20) Scores: Average Presence of Eye Gaze Maintenance over a Face Area for the Whole Trial Duration

  **Eye gaze maintenance presence over whole trial duration**   **Low Ns (Mean±SD)**   **High Ns (Mean±SD)**
  ------------------------------------------------------------- ---------------------- -----------------------
  *Eye area*                                                                           
  * *High fearful                                               0.29±0.35              0.10±0.22
  * *Medium fearful                                             0.30±0.34              0.10±0.22
  * *Low fearful                                                0.27±0.30              0.10±0.24
  * *High happy                                                 0.28±0.33              0.10±0.22
  * *Medium happy                                               0.27±0.32              0.11±0.25
  * *Low happy                                                  0.30±0.32              0.09±0.23
  * *Neutral                                                    0.30±0.32              0.11±0.24
                                                                                        
  *Mouth area*                                                                         
  * *High fearful                                               0.15±0.27              0.48±0.42
  * *Medium fearful                                             0.13±0.26              0.44±0.40
  * *Low fearful                                                0.13±0.26              0.47±0.40
  * *High happy                                                 0.17±0.29              0.48±0.44
  * *Medium happy                                               0.16±0.27              0.48±0.41
  * *Low happy                                                  0.12±0.26              0.49±0.42
  * *Neutral                                                    0.12±0.25              0.44±0.42

###### Eye Movements Over Facial Expressions During a Gender Discrimination Task, After 7 Days Treatment with Citalopram or Placebo in Subjects with High Neuroticism Scores

                                                          **Citalopram (Mean±SD)**   **Placebo (Mean±SD)**
  ------------------------------------------------------- -------------------------- -----------------------
  *Scanpath lenghth (pxl)*                                                           
  * *High fearful                                         46.54±32.75                51.31±21.37
  * *Medium fearful                                       44.28±33.48                65.52±32.27
  * *Low fearful                                          43.72±28.54                45.61±18.15
  * *High happy                                           49.43±28.86                50.84±16.55
  * *Medium happy                                         46.37±30.16                51.55±28.1
  * *Low happy                                            41.37±30.80                51.52±27.53
  * *Neutral                                              41.71±22.22                46.14±17.99
                                                                                      
  *Scanning time (ms)*                                                               
  * *High fearful                                         239.53±5                   210.39±36.82
  * *Medium fearful                                       238.95±5.93                212.76±32.97
  * *Low fearful                                          240.43±4.52                217.51±31.21
  * *High happy                                           235.59±11.6                209.11±32.69
  * *Medium happy                                         238.41±6.78                213.89±35.32
  * *Low happy                                            235.83±13.75               206.88±45.03
  * *Neutral                                              237.74±6.06                208.62±38.96
                                                                                      
  *Gaze maintenance presence over whole trial duration*                              
  * *High fearful                                         0.98±0.04                  0.9±0.1
  * *Medium fearful                                       0.99±0.02                  0.88±0.13
  * *Low fearful                                          1±0.01                     0.92±0.07
  * *High happy                                           0.95±0.07                  0.89±0.11
  * *Medium happy                                         0.98±0.04                  0.9±0.08
  * *Low happy                                            0.98±0.05                  0.86±0.17
  * *Neutral                                              0.98±0.04                  0.88±0.11

Eye movement parameters indicate the average area explored over each face type (scanpath length), the average time spent scanning each face type (scanning time), and whether eye gaze was maintained fixed over each face type for the whole duration of a trial (gaze maintenance).
